 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Watchers	9
52-Wk Low	$0.45
52-Wk High	$1.24

Market Cap	$58.16M
Volume (M)	89,689.00
52-Wk High	$1.24
52-Wk Low	$0.45

Current Price	$0.90
Prev Close	$0.88
Open	$0.90
Dividend Yield	0.00%
50-Day Moving Average	$0.9874
Beta	1.41
Avg. Volume	219,847.35
PE Ratio	-2.55

52-Week High	$1.24
52-Week Low	$0.45
Market Capitalization	$58.16M
EPS	-$0.3529
Price to Book	1.97
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-0.86

CRTPF Cardiol Therapeutics Inc - Ordinary Shares - Class A

About

Feed

News

Fundamentals